179 related articles for article (PubMed ID: 17272984)
1. Melanoma immunology: past, present and future.
Parmiani G; Castelli C; Santinami M; Rivoltini L
Curr Opin Oncol; 2007 Mar; 19(2):121-7. PubMed ID: 17272984
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
3. Recent advances and hurdles in melanoma immunotherapy.
Jandus C; Speiser D; Romero P
Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
5. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
6. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
8. Tumor immunotherapy in melanoma: on the dawn of a new era?
Wilcox R; Markovic SN
Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
10. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
12. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
Tuettenberg A; Schmitt E; Knop J; Jonuleit H
J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
[TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy for melanoma: current status and future directions.
Terando AM; Faries MB; Morton DL
Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
[TBL] [Abstract][Full Text] [Related]
15. The human T cell response to melanoma antigens.
Romero P; Cerottini JC; Speiser DE
Adv Immunol; 2006; 92():187-224. PubMed ID: 17145305
[TBL] [Abstract][Full Text] [Related]
16. Immunology of melanoma.
Mukherji B
Clin Dermatol; 2013; 31(2):156-65. PubMed ID: 23438379
[TBL] [Abstract][Full Text] [Related]
17. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
[TBL] [Abstract][Full Text] [Related]
18. Active-specific immunization against melanoma: is the problem at the receiving end?
Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
[TBL] [Abstract][Full Text] [Related]
19. Melanoma vaccines.
Chapman PB
Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutic approachs in melanoma].
Mortier L; Marchetti P; Gordower L; Charbonnier-Hatzfeld AS; Toungouz M; Velu T
Rev Med Brux; 2004 Jun; 25(3):153-9. PubMed ID: 15291447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
